The continuing role of PSA in the detection and management of prostate cancer

Kurt Miller; Per-Anders Abrahamsson; Koichiro Akakura; Frans M. J. Debruyne; Christopher P. Evans; Laurence Klotz

doi:10.1016/j.eursup.2006.12.001

The continuing role of PSA in the detection and management of prostate cancer

Kurt Miller, Per-Anders Abrahamsson, Koichiro Akakura, Frans M. J. Debruyne, Christopher P. Evans, Laurence Klotz

Research output: Contribution to journal › Article › peer-review

Abstract

Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Original language	English
Pages (from-to)	327-333
Journal	European Urology. Supplement
Volume	6
Issue number	3
DOIs	https://doi.org/10.1016/j.eursup.2006.12.001
Publication status	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Subject classification (UKÄ)

Clinical Medicine

Free keywords

PSA doubling time
prostate cancer
PSA
PSA velocity

Access to Document

10.1016/j.eursup.2006.12.001

Cite this

@article{76e9754f1af243ae9b1096ef2e4cd0c9,

title = "The continuing role of PSA in the detection and management of prostate cancer",

abstract = "Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.",

keywords = "PSA doubling time, prostate cancer, PSA, PSA velocity",

author = "Kurt Miller and Per-Anders Abrahamsson and Koichiro Akakura and Debruyne, \{Frans M. J.\} and Evans, \{Christopher P.\} and Laurence Klotz",

year = "2007",

doi = "10.1016/j.eursup.2006.12.001",

language = "English",

volume = "6",

pages = "327--333",

journal = "European Urology. Supplement",

issn = "1569-9056",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - The continuing role of PSA in the detection and management of prostate cancer

AU - Miller, Kurt

AU - Abrahamsson, Per-Anders

AU - Akakura, Koichiro

AU - Debruyne, Frans M. J.

AU - Evans, Christopher P.

AU - Klotz, Laurence

PY - 2007

Y1 - 2007

N2 - Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.

AB - Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy. (c) 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved.

KW - PSA doubling time

KW - prostate cancer

KW - PSA

KW - PSA velocity

UR - https://www.scopus.com/pages/publications/33846408703

U2 - 10.1016/j.eursup.2006.12.001

DO - 10.1016/j.eursup.2006.12.001

M3 - Article

SN - 1569-9056

VL - 6

SP - 327

EP - 333

JO - European Urology. Supplement

JF - European Urology. Supplement

IS - 3

ER -

The continuing role of PSA in the detection and management of prostate cancer

Abstract

UN SDGs

Subject classification (UKÄ)

Free keywords

Access to Document

Other files and links

Fingerprint

Cite this